This week in therapeutics




Licensing status

Publication and contact information


myelogenous leukemia (AML)

MicroRNA-196b (miR-196b); miR-21

Patient sample, mouse and in vitro studies suggest inhibiting miR-196b and miR-21 could help treat homeobox A9 (HOXA9)-driven AML. Translocations that increase the expression of HOXA9 drive a subset of AML cases with poor prognosis. In samples from patients with AML, HOXA9, miR-196 and miR-21 were coordinately upregulated. In a human leukemia cell line, HOXA9 was bound to the promoter of miR-196 and miR-21. In bone marrow cells from Hoxa9 knockout mice, miR-196b and miR-21 levels were lower than those in cells from wild-type mice. In a mouse model of Hoxa9-dependent AML, injection of antagomirs targeting miR-196b or miR-21
decreased leukemia-initiating activity and lethality compared with injection of control antagomirs. Next steps could include testing the antagomirs in clinical human AML isolates.

SciBX 7(4); doi:10.1038/scibx.2014.110
Published online Jan. 30, 2014

Patent and licensing status undisclosed

Velu, C.S. et al. J. Clin. Invest.; published online Dec. 16, 2013;
Contact: H. Leighton Grimes, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio